Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Consumer Safety topic
No spam. Unsubscribe anytime.
Long public hearing lays out health risks, industry concerns as committee considers Kratom Consumer Protection Act
Summary
SB 557 would set a minimum purchase age (21), require testing and labeling, ban synthetic concentrated alkaloids and establish licensing and packaging standards for kratom; clinicians and treatment providers described rising dependence and emergency visits while industry and some consumers pushed for distinction between whole‑leaf kratom and synthetic concentrates.
Senate bill 557, the Kratom Consumer Protection Act, drew extended testimony from clinicians, public‑health advocates, business owners and consumers debating how to regulate a product that many witnesses described as sitting between a dietary supplement and a psychoactive substance.
Sponsor Senator Deborah Uchler framed the proposal as a consumer‑protection and youth‑safety measure that would raise the sales age to 21, require labeling of alkaloid content, cap potency for synthetic/semi‑synthetic derivatives, require child‑resistant packaging for certain formulations, forbid marketing to minors and create enforcement tools and licensing authority for the Department of Health and Human Services. She emphasized the product's opioid‑receptor pharmacology and the policy rationale for regulation rather than prohibition.
Medical witnesses, including addiction specialists and clinicians who treat withdrawal, described increasing presentations involving high‑potency products and synthetic derivatives (notably 7‑OH variants). Nurse practitioner Renee King recounted treating severe kratom withdrawal and patient cases that later required opioid‑use‑disorder care. Dartmouth addiction researcher Dr. Cornell Stancho and others described the market's three waves — raw leaf, solvent extracts, and highly concentrated semi‑synthetic/synthetic products — and recommended caps, research provisions and labeling improvements.
Industry representatives and vendors urged nuanced policy that distinguishes traditional leaf products (which some patrons say help with pain or mood) from concentrated synthetic products marketed in candy‑like forms. The Global Kratom Coalition, trade associations and small vendors asked the committee to avoid onerous packaging and implementation burdens that could force legitimate vendors out of the market. Several witnesses suggested the bill adopt best‑practice consumer‑safety language used in other states, and some recommended specific technical edits: clarity on THCA/isomers, per‑serving versus per‑package alkaloid reporting, and exemptions for traditional tea preparations.
Committee members pressed for consistency in chemical definitions, enforceable alkaloid limits based on dry‑weight milligram caps, and clear prohibition language targeting synthetic or concentrated 7‑OH products. Multiple witnesses urged the committee to balance consumer safety, research access and the clinical realities seen by treatment providers.
No final committee vote was recorded; senators indicated amendments and cross‑state comparisons would inform next steps.
